Effects of empagliflosin on the course of non-alcoholic fatty liver disease in experiment
https://doi.org/10.33647/2713-0428-17-3E-144-146
Abstract
Effects of the SGLT-2 drug of the group of empagliflozin inhibitors on the biochemical and histological picture of non-alcoholic fatty liver disease in mice was evaluated.
About the Authors
A. V. Bunyat
Saint Petersburg State Chemical and Pharmaceutical University of the Ministry of Health Сare of Russia
Russian Federation
Russian Federation
197376, Saint Petersburg, Professora Popova Str., 14, let. A
D. S. Sukhanov
Saint Petersburg State Chemical and Pharmaceutical University of the Ministry of Health Сare of Russia
Russian Federation
Russian Federation
Dr. Sci. (Med.), Prof.,
197376, Saint Petersburg, Professora Popova Str., 14, let. A
References
1. Castro R.E., Diehl A.M. Towards a definite mouse model of NAFLD. Journal of Hepatology. 2018;69:272–274.
2. Haya A., Ilhame D., Maha V., et al. Metabolic signature of obesity-associated insulin resistance and type 2 diabetes. J. of Transl. Med. 2019;19:348.
3. Monami M., Nardini C., Mannucci E. Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials. Diabetes Obes. Metab. 2014;16:457– 466.
4. Tahara A., Kurosaki E., Yokono M., Yamajuku D., Kihara R., Hayashizaki Y., Takasu T., Imamura M., Li Q., Tomiyama H., Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur. J. Pharmacol. 2013;715:246–255.
Review
For citations:
Bunyat A.V., Sukhanov D.S. Effects of empagliflosin on the course of non-alcoholic fatty liver disease in experiment. Journal Biomed. 2021;17(3E):144-146. (In Russ.) https://doi.org/10.33647/2713-0428-17-3E-144-146
Views:
326
Email this article 
